This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuovo, G. J. Articles by French, D. L. Search for Related Content PubMed PubMed Citation Articles by Nuovo, G. J. Articles by French, D. L.

Correlation of the in Situ Detection of Polymerase Chian Reaction-amplified Metalloproteinase Complementary DNAs and Their Inhibitors with Prognosis in Cervical Carcinoma¹

Departments of Pathology [G. J. N., P. B. M., A. S., D. L. F.] and Obstetrics and Gynecology [G. J. N., F. V.], State University of New York, Stony Brook, New York 11794-8691

The purpose of this study was to correlate the presence of matrix metalloproteinase (MMP)-9 and MMP-2 and tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 mRNAs, detected in serial sections using the reverse transcriptase in situ PCR technique, with prognosis in 23 cases of cervical carcinoma. PCR-amplified MMP and TIMP cDNA were restricted to the invasive cancers cells and the surrounding stromal cells. The ratios of cancer and stromal cells expressing MMP-9 and MMP-2 to those expressing TIMP-1 and TIMP-2 were approximently 1 in those cancers with a good prognosis. This MMP:TIMP ratio in the cancer and stromal cells with a poor prognosis was significantly increased to 5.4 and 3.4 (P < 0.0001), respectively, reflecting a marked reduction in the TIMP detection rate in cancers with a poor prognosis. In cervical cancer cell lines SiHa and HeLa, the MMP:TIMP ratio was also close to 1 and, interestingly, these cell lines are invasive but rarely metastatic in nude mice. These data suggest that the balance of MMP-9 and MMP-2 to TIMP-1 and TIMP-2 expression is an essential factor in the aggressiveness of cervical cancer.

¹ Supported by grants from Perkin-Elmer Corporation and the Lewis Foundation (20640), the Center for Biotechnology of the State of New York (X383K), (GJN) and the American Heart Association National Center (DLF).

² To whom requests for reprints should be addressed.

Received 7/26/94. Accepted 11/11/94.

This article has been cited by other articles:

				A. Behren, C. Simon, R. M. Schwab, E. Loetzsch, S. Brodbeck, E. Huber, F. Stubenrauch, H. P. Zenner, and T. Iftner Papillomavirus E2 Protein Induces Expression of the Matrix Metalloproteinase-9 via the Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Pathway Cancer Res., December 15, 2005; 65(24): 11613 - 11621. [Abstract] [Full Text] [PDF]

				S. Smola-Hess, J. Pahne, C. Mauch, P. Zigrino, H. Smola, and H. J. Pfister Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products J. Gen. Virol., May 1, 2005; 86(5): 1291 - 1296. [Abstract] [Full Text] [PDF]

				S. Singh, U. P. Singh, J. K. Stiles, W. E. Grizzle, and J. W. Lillard Jr. Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion Clin. Cancer Res., December 15, 2004; 10(24): 8743 - 8750. [Abstract] [Full Text] [PDF]

				D. Trudel, Y. Fradet, F. Meyer, F. Harel, and B. Tetu Significance of MMP-2 Expression in Prostate Cancer: an Immunohistochemical Study Cancer Res., December 1, 2003; 63(23): 8511 - 8515. [Abstract] [Full Text] [PDF]

				B. Bodner-Adler, K. Bodner, O. Kimberger, K. Czerwenka, S. Leodolter, and K. Mayerhofer MMP-1 and MMP-2 Expression in Uterine Leiomyosarcoma and Correlation With Different Clinicopathologic Parameters Reproductive Sciences, October 1, 2003; 10(7): 443 - 446. [Abstract] [PDF]

				T. Okamoto, R. Niu, and S. Yamada Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary Mol. Hum. Reprod., October 1, 2003; 9(10): 569 - 575. [Abstract] [Full Text] [PDF]

				B.-C. Sheu, H.-C. Lien, H.-N. Ho, H.-H. Lin, S.-N. Chow, S.-C. Huang, and S.-M. Hsu Increased Expression and Activation of Gelatinolytic Matrix Metalloproteinases Is Associated with the Progression and Recurrence of Human Cervical Cancer Cancer Res., October 1, 2003; 63(19): 6537 - 6542. [Abstract] [Full Text] [PDF]

				T. A. Fehniger, M. A. Cooper, G. J. Nuovo, M. Cella, F. Facchetti, M. Colonna, and M. A. Caligiuri CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity Blood, April 15, 2003; 101(8): 3052 - 3057. [Abstract] [Full Text] [PDF]

				G. J. Nuovo Co-labeling Using In Situ PCR: A Review J. Histochem. Cytochem., November 1, 2001; 49(11): 1329 - 1340. [Abstract] [Full Text] [PDF]

				G. J. Nuovo, C. Morrison, P. Porcu, M. A. Caligiuri, and S. Suster In Situ Determination of T-cell Receptor Beta Expression Patterns J. Histochem. Cytochem., February 1, 2001; 49(2): 139 - 146. [Abstract] [Full Text]

				B.-C. Sheu, S.-M. Hsu, H.-N. Ho, H.-C. Lien, S.-C. Huang, and R.-H. Lin A Novel Role of Metalloproteinase in Cancer-mediated Immunosuppression Cancer Res., January 1, 2001; 61(1): 237 - 242. [Abstract] [Full Text]

				M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]

				D. A. Calhoun, M. Lunoe, Y. Du, and R. D. Christensen Granulocyte Colony-Stimulating Factor Is Present in Human Milk and Its Receptor Is Present in Human Fetal Intestine Pediatrics, January 1, 2000; 105(1): e7 - e7. [Abstract] [Full Text] [PDF]

				G. J. Nuovo, T. W. Plaia, S. A. Belinsky, S. B. Baylin, and J. G. Herman In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis PNAS, October 26, 1999; 96(22): 12754 - 12759. [Abstract] [Full Text] [PDF]

				H. Miyake, I. Hara, K. Gohji, K. Yamanaka, S. Hara, S. Arakawa, M. Nakajima, and S. Kamidono Relative Expression of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 in Mouse Renal Cell Carcinoma Cells Regulates Their Metastatic Potential Clin. Cancer Res., October 1, 1999; 5(10): 2824 - 2829. [Abstract] [Full Text] [PDF]

				G.J. Nuovo, R.J. Hohman, G.A. Nardone, and I.A. Nazarenko In Situ Amplification Using Universal Energy Transfer-labeled Primers J. Histochem. Cytochem., March 1, 1999; 47(3): 273 - 280. [Abstract] [Full Text]

				M. BOSSÉ, J. CHAKIR, M. ROUABHIA, L.-P. BOULET, M. AUDETTE, and M. LAVIOLETTE Serum Matrix Metalloproteinase-9:Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Steroid Responsiveness in Moderate to Severe Asthma Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 596 - 602. [Abstract] [Full Text]

				N. Johansson, M. Vaalamo, S. Grenman, S. Hietanen, P. Klemi, U. Saarialho-Kere, and V.-M. Kahari Collagenase-3 (MMP-13) is Expressed by Tumor Cells in Invasive Vulvar Squamous Cell Carcinomas Am. J. Pathol., February 1, 1999; 154(2): 469 - 480. [Abstract] [Full Text] [PDF]

				K. R. BEREND, A. P. TOTH, J. M. HARRELSON, L. J. LAYFIELD, L. A. HEY, and S. P. SCULLY Association between Ratio of Matrix Metalloproteinase-1 to Tissue Inhibitor of Metalloproteinase-1 and Local Recurrence, Metastasis, and Survival in Human Chondrosarcoma J. Bone Joint Surg. Am., January 1, 1998; 80(1): 11 - 7. [Abstract] [Full Text] [PDF]